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Summary
Burkitt lymphoma is the most common malignancy in children in Malawi,
the world’s poorest country, where there is a long history of treating this
disease using a 28-day cyclophosphamide-based protocol. Stage III/IV dis-
ease has had poor outcomes. In an attempt to improve the outcome for
higher stage disease, anthracyclines were added to the existing protocol.
The disease-free (DFS) and overall survival (OS) of 58 children with cyto-
logically confirmed Burkitt lymphoma admitted during 2012–2014 and
treated using this protocol were calculated. Six (10%) children had stage I
disease, ten (17%) stage II and 42 stage III or IV (73%). Overall 12-month
DFS (OS) was 685% (729%); for stage I disease 100% (100%), stage II
562% (60%), stage III/IV 663% (722%). The DFS was significantly
improved from the previous protocol (P = 8 9 104). The addition of
doxorubicin to stage III and IV disease resulted in a markedly improved
DFS. Anthracyclines are deliverable in resource-poor settings and possibly
improve the survival of children with Burkitt lymphoma.
Keywords: Burkitt lymphoma, anthracyclines, resource-challenged
countries, endemic, chemotherapy.
Endemic Burkitt lymphoma (BL) is the most common
tumour in Malawian children, accounting for almost 50% of
all childhood tumours. The frequency of this tumour in
Malawi is associated with the presence of holoendemic
malaria and the early acquisition of Epstein–Barr Virus
(EBV). The mechanism is thought to involve the interaction
of the malarial parasite and EBV-infected cells (Molyneux
et al, 2012).
Endemic BL is very sensitive to chemotherapy, particularly
cyclophosphamide, as well as intrathecal methotrexate for
central nervous system disease (Nkrumah et al, 1985; Traore
et al, 2011; Magrath, 2012; Molyneux et al, 2012). Sporadic
BL in resource-rich countries has a disease-free survival
(DFS) greater than 90% even in advanced stage disease
(Patte et al, 2007; Gerrard et al, 2008) but this requires very
intensive chemotherapy, which is neither feasible nor safe in
most low-income countries. As a result, countries, such as
Malawi, which have previously tried simplified versions of
the LMB protocols (B cell Non Hodgkin Lymphoma and B
Acute Lymphoblastic Leukaemia schedules from the Societe
Francaise d’Oncologie Pediatrique) with unacceptable toxic-
ity, have developed protocols appropriate to their setting,
both in terms of length of treatment and intensity (Hesseling
et al, 2003, 2012; Depani et al, 2015). The modified LMB 89
protocol was a 77-day regimen with reduced doses of
methotrexate (2 vs. 3 g/m2), vincristine, 15 mg/m2 vs. 2 mg/
m2; adriamycin and etoposide were not included. No radio-
therapy was available. Despite these reductions in
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chemotherapy and exclusions of Stage 4 disease and children
with human immunodeficiency virus (HIV) infection, deaths
during treatment were 23% and a further 23% abandoned
treatment (Hesseling et al, 2003).
Using a range of protocols between 1997 and 2010 with a
duration between 28 and 57 days, the DFS was approxi-
mately 50% for all stages but with an average event-free sur-
vival of approximately 30% for stage III and IV disease
(Table I) (Hesseling et al, 2005, 2008a, 2009, 2012; Depani
et al, 2015). The rescue rate at relapse has remained around
30% over this time (Hesseling et al, 2008b). During this per-
iod, the oncology unit at the Queen Elizabeth Central Hospi-
tal in Blantyre, Malawi has improved supportive care and
introduced treatment protocols to treat several previously
untreated cancers, such as acute lymphoblastic leukaemia
(Chagaluka et al, 2013; Isra€els et al, 2013a; Carey et al,
2014).
With this experience and the desire to improve the out-
come of higher stage BL without an increase in the dura-
tion of stay for the families, doxorubicin at a total dose of
Table I. Comparative table of patient details and outcomes using Malawi protocols for treatment of Burkitt lymphoma.
Malawi 1997
(Hesseling
et al, 2003) a
Malawi 2000
(Hesseling
et al, 2005) b
Malawi 2002
(Hesseling
et al, 2008a) c
Malawi 2003
(Hesseling
et al, 2008a) d
Malawi 2006
(Hesseling
et al, 2009) e
Malawi 2010
(Depani
et al, 2015) f
Malawi
2012–14 g
Total patients (n) 44 42 129 140 40 70 58
Patient characteristics
Median age, years 7 7 7 6 7 8 7
Male:Female ratio 14 25 16 13 13 15 093
Malaria positive 23% 26% + + 17% 26% 132%
HIV positive 5% ƚ 2% ƚ 2% + 2% 3% 3%
Malnourished 77% 67% + + 50% 60% 43%
Staging
Stage I 17% 12% 6% 8% 3% 4% 10%
Stage II 9% 19% 18% 20% 22% 29% 17%
Stage III 50% 50% 50% 57% 60% 30% 73%
Stage IV 24% 19% 26% 15% 15% 37%
Sites of disease
Face 79% 74% 68% 70% 70% 64% 57%
Abdomen 61% 55% 74% 71% 70% 47% 48%
Paraplegia 3% 12% 11% 11% 15% 17% 10%
CSF 1% 5% 12% + 15% 26% 16%
BM 17% 14% 16% + 25% 9% 13%
Outcomes
On-treatment deaths 23% 26% 8% 6% 25% 3% 12%
Absconded 23% 0% 1% + 75% 3% 5%
CCR 89% 96% 74% 87% 88% 81% 82%
Rescue at Relapse 20% 29% 29% 23% 40% 29% 36%
Overall DFS 57%* 33% 50%* 57%* 48% 45% 706%
Stage I DFS 90% 50% 55% + 100% 100% 100%
Stage II DFS + 50% 53% + 55% 83% 56%
Stage III DFS 52% 24% 48% + 50% 24% 663%
Stage IV DFS ƚ 25% 10% + 17% 32%
Stage III/IV DFS + 243% 35% + 434% 284% 663%
Ara-C, cytarabine; BM, bone marrow; CCR, complete clinical response; CPM, cyclophosphamide; CSF, cerebrospinal fluid; DFS, disease-free sur-
vival; HC, hydrocortisone; HIV, human immunodeficiency virus; IT, intrathecal; MTX, methotrexate; VCR, vincristine.
(a) Modified LMB89 group B protocol: doxorubicin omitted, dose reduction of iv MTX, CPM and Ara-C (b) IT MTX/HC + COP (CPM
300 mg/m2; VCR 1 mg/m2; prednisolone 60 mg/m2) day 1 for Stage I/II; days 1,8 for Stage III/IV + COMP (CPM 500 mg/m2; VCR 2 mg/m2; iv
MTX 2 g/m2; prednisolone 60 mg/m2) day 22 + CPM 40 mg/kg iv + IT MTX/HC 15 mg days 1,8 and 15 + CPM 40 mg/kg iv days 29, 43 and
57 for Stage III/IV (d) CPM 40 mg/kg (iv for first dose then po) + IT MTX/HC 125 mg days 1,8 and 15 + CPM 40 mg/kg po days 29, 43 and
57 for Stage III/IV (e) CPM 40 mg/kg day 1, CPM 60 mg/kg days 8, 18 and 28, IT MTX/HC 125 mg days 1, 8, 18 and 28 (f) CPM (40 mg/kg
iv with maximum total dose of 16 g on day 1; 60 mg/kg po/iv with maximum total dose of 24 g on days 8, 18 and 28), prednisolone 60 mg/
m2/day in 2 divided doses days 1–5, VCR (15 mg/m2 with maximum dose of 2 mg on days 1, 8, 18 and 28) and IT MTX (125 mg/dose) and
IT HC (12 mg/dose) on days 1, 8, 18 and 28 (g) as per (f) with the addition of Doxorubicin (stage III and IV) days 15 and 28 and CPM dose
40 mg/kg on days 15, 28.
+ not reported. ƚ excluded from study.
*DFS for stages I–III only.
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120 mg/m2 was added to the previous protocol that was
developed in 2010 (Depani et al, 2015) and administered
during week two and four of the treatment protocol. This
dose was thought to offer potential benefits with minimal
risk of cardiotoxicity and is used in the majority of children
at similar doses for the treatment of non-haematopoietic
tumours. It was felt that, by adding this on Day 15 and
Day 28, the risk of inducing tumour lysis syndrome was
lessened.
Subjects and methods
The Queen Elizabeth Central Hospital (QECH) is a large,
public, government referral hospital in Blantyre, Malawi. The
paediatric department admits 28 000 children a year, with
90 000 children seen in the emergency unit and outpatients
departments. The paediatric oncology unit is a 23-bedded
unit housed within the paediatric department and receives
about 320 new patients a year.
Children between the ages of one and 16 years of age
admitted to the oncology ward at the QECH (all patients
aged 16 years or under with a suspected cancer diagnosis are
admitted to the oncology ward) with a cytologically con-
firmed diagnosis of BL were included in this study. Informed
consent was obtained from the patients/guardians prior to
commencement of treatment.
Initial examination and investigations on all children with
a clinical diagnosis of BL included recording of all tumour
sites by clinical examination, chest X ray and abdominal
ultrasound. Weight, height and mid-arm circumference were
measured. Laboratory investigations included a full blood
count, rapid HIV test, malaria test, stool and urine micro-
scopy. Under ketamine sedation a fine needle aspirate (FNA)
was taken from an accessible tumour site together with a
bone marrow aspirate (BMA) and cerebrospinal fluid (CSF);
(cytospin was not available). Slides of FNA, BMA and CSF
were stained with Rapidiff stain kit (Clinical Service Labora-
tory, QECH 3) and photographs of the slides, using a Jenoptic
camera (CT 13 with Prog Res Mac Capture Pro software)
based on an Olympus microscope (CX31) were transmitted
electronically for cytological diagnosis in Newcastle, UK by
an experienced haematologist (Carey et al, 2014). The initial
intrathecal chemotherapy was given at the time of the diag-
nostic lumbar puncture. Disease was staged according to the
St Jude non-Hodgkin lymphoma staging system although it
is appreciated that this is done without cross sectional imag-
ing (Murphy, 1980). Due to the absence of some bone mar-
row and CSF results all stage III and IV tumours were
analysed together to avoid inaccuracies of grading between
the higher grades of tumour.
Patients were treated on a 28-day schedule (Malawi 2012–
2014 protocol). Prednisolone 60 mg/m2 was given orally in 2
divided doses on days 1–5; cyclophosphamide (40 mg/kg iv
with maximum total dose of 16 g on days 1, 15 and 28;
60 mg/kg iv with maximum total dose of 24 g on day 8),
vincristine (15 mg/m2 with maximum dose of 2 mg on days
1, 8, 15 and 28), doxorubicin 60 mg/m2 on days 15 and 28
(for stage III and IV disease only) and IT methotrexate
(125 mg/dose) and hydrocortisone (12 mg/dose) on days 1,
8, 15 and 28 (Fig 1).
Appropriate supportive care was provided (Israels et al,
2013b) that included the following: hyperhydration and allop-
urinol during the induction chemotherapy with weekly full
blood counts and delay of chemotherapy if the neutrophil
count was <10 109/l, the patient was febrile or clinically unfit
for treatment. Packed red cells were given if the haemoglobin
fell below 50 g/l or for symptomatic anaemia. Platelets transfu-
sions are not routinely available and were therefore not used.
Nutritional supplementation in the form of a protein-rich sup-
plement was given to all patients. Children who were febrile
Fig 1. Treatment Schedule for higher stage
Burkitt Lymphoma in Malawi. IT, intrathecal;
MTX, methotrexate
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and neutropenic were treated according to the local protocol
(Isra€els et al, 2009). Echocardiograms were not performed.
Children were kept in hospital for the duration of their
28-day treatment and discharged when clinically stable. Chil-
dren were reviewed at two, six and 12 months from the start
of treatment and attempts were made to trace children who
failed to attend.
The primary endpoint was 1-year DFS. Events were death,
disease progression or relapse. Response to treatment was
assessed on day 28. Complete clinical response (CCR) was
defined as the absence of any visible or palpable disease either
clinically or on ultrasound examination. Partial response
was >50% clinical reduction in tumour volume and a poor
response/resistant disease was <50% clinical reduction.
Patients who did not achieve CCR or who relapsed were
offered rescue chemotherapy. Haematological and infectious
side effects of treatment were graded according to the National
Cancer Institute common toxicity criteria for adverse events
(CTCAE v 40; http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_
4.03_2010-06-14_QuickReference_8.5x11.pdf).
Disease-free survival was defined as time elapsed from
diagnosis to first event, which was tumour recurrence or
progression. OS was defined as time elapsed from diagnosis
to death. Features with categorical outcomes were analysed
using log-rank tests and Kaplan–-Meier plots. Binary and
continuous features were tested using Cox Proportional
Hazards models and tested to confirm proportionality of
hazards. All statistical analyses were performed using R
(v3.2.0) (https://cran.r-project.org/manuals.html).
Results
Eighty-four children were admitted with suspected BL
between March 2012 and January 2014 (Fig 1). Sixteen were
excluded from the analysis, six were treated on different pro-
tocols as it was clinically thought that they did not have BL
and only on later cytological examination were found to have
BL [this is in comparison with nine patients in the previous
study using the protocol developed in 2010 (Depani et al,
2015)]; seven children were lost to follow up despite exten-
sive efforts to trace them [compared with 8 in the previous
study using the protocol developed in 2010 (Depani et al,
2015)] and three absconded during initial treatment [com-
pared to 2 in the previous study (Depani et al, 2015)]. Of
the remaining 68 children with cytological confirmation of
BL, 10 died before the diagnosis was confirmed and conse-
quently received no treatment. This relatively high number is
thought to be partly due to the fact that more children are
presenting very late from neighbouring Mozambique. Analy-
sis was performed on the remaining 58 children who were
treated on the Burkitt protocol and for whom follow-up data
was available. The previous study using the protocol devel-
oped in 2010 (Depani et al, 2015) was used as a comparator
and the analysis for this study was performed in the same
way. No significant differences with regard to clinical
parameters and early events or treatment completion rates
were found between the 2 studies. (Table II).
The median age at presentation was 7 years (242–18)
with a male: female ratio of 093:1. Median duration of
symptoms was 30 days (4–180). Three patients (5%) were
HIV reactive at diagnosis. Twenty-five (43%) children were
malnourished [assessed by mid upper arm circumference
(MUAC), weight for height and weight for age less than 3rd
percentile on at least one parameter) at presentation. Malar-
ial parasites were seen on a thick blood film at presentation
in 7 (132%) children.
Using the St Jude staging classification (Murphy, 1980) 6
(10%) children had stage I disease, 10 (17%) stage II, and 42
stage III or IV (73%). Thirty-four of the 42 children with
Stage III/IV disease presented with clinically palpable abdom-
inal masses, the remaining 8 were staged on ultrasound alone
or with positive CSF or bone marrow. The site of disease is
described in Table II.
Table II. Comparative figures for the two most recent Malawi Bur-
kitt protocols.
2010 study
(Depani
et al, 2015)
2012–2014
study P value
Confirmed Burkitt
lymphoma
75 78
No follow-up post-
treatment
8 7
Absconded 2 3
Died on treatment 2 7
Dead prior to treatment 5 10
Completed treatment
with follow-up
58 51 028
Stage
1 3 6
2 17 10
3 + 4 40 42 007
Age (years)
Median (range) 8 (3–16) 7 (24–18) 060
HIV Status
Positive 2 3
Negative 56 48 066
Site
Face 36 (60%) 33 (57%)
Abdomen 28 (47%) 28 (48%)
Orbit 12 (20%) 13 (22%)
Bone 4 (7%) 2 (3%)
Limb 2 (3%) 1 (2%)
Paraplegia 12 (20%) 6 (10%)
CSF 18 (30%) 7 (13 not done)
Bone marrow
infiltration
6 (10%) 5 (19 not done)
CSF, cerebrospinal fluid; HIV, human immunodeficiency virus.
Continuous variables (age) were compared using student’s t test.
Categorical data were compared using chi-squared tests of associa-
tion and Fisher’s exact test.
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Seven children (12%) died during treatment; all appeared
to be septic at the time of death although only one blood
culture was positive (salmonella typhi). Two of these children
were HIV positive. Five children died during the first
2 weeks of treatment (four prior to doxorubicin) the remain-
ing two in week four and just after completion of treatment
but whilst still inpatients. None appeared to have progressive
disease at the time of death. All seven children who died had
stage III/IV disease. Six children with stage III/IV disease had
their second dose of chemotherapy (day 8) delayed (3–
13 days), five had their third dose of chemotherapy (day 15)
delayed and the fourth dose of chemotherapy (day 28) was
delayed in two children. Four children had CTCAE grade 3
and 5 grade 4 leucopenia prior to day 8 chemotherapy, seven
had grade 3 and eight grade 4 prior to day 15 chemotherapy
and seven had grade 3 and five grade 4 prior to their day 28
chemotherapy.
Of the 51 children who completed treatment 42 (82%)
had a CCR to treatment, seven (14%) a poor response
(<50%) and two (4%) had no response. The two children
who had no response remain alive and disease-free, one had
surgical removal of disease in her ovary (mainly necrotic
with few viable cells) followed by two further courses of
chemotherapy. The other child did not receive any more
therapy and remains alive and well 12 months after diagno-
sis. A fine needle aspirate post-treatment showed mainly
necrotic tissue.
The 12-month DFS was 685% [standard error (SE) 
66%), and was 100% for stage I disease, 562%
(SE  165%) for stage II and 663% (SE  80%) for stage
III/IV (Fig 2). Overall survival (OS) at 12 months was 729%
(SE  62%) and was 100% for stage I disease, 60%
(SE  155%) for stage II and 722% (SE  75%) for stage
III/IV (Fig 2).
Eleven (9%) children relapsed. One was stage I at relapse
(survived), 3 were stage II (1 survived), 4 stage III (2 sur-
vived) and 3 stage IV (none survived). Time to relapse ran-
ged from 20 to 71 months (median 50 months). Seven
(64%) children subsequently died, six of their disease and
one from presumed sepsis, the remaining four (36%) remain
alive and disease-free. Children were treated on the Malawi
relapse protocol, which includes cyclophosphamide and high
dose (1 g/m2 iv) methotrexate. Follow-up of the survivors
was over a period of 41–238 months (median 131 months)
with only one having follow-up of less than 11 months
(41 months) and the majority being seen at their 1 year fol-
low-up visit.
Univariate analysis showed that significant factors at pre-
sentation affecting DFS were pedal oedema [P = 002, hazard
ratio (HR) 334, 95% confidence interval (CI) 117 and 95]
and haemoglobin level (Hb) (P = 00008, HR 066, 95% CI
052 and 084). For OS, significant presenting factors were
pedal oedema (P = 001, HR 449, 95% CI 153 and 132)
and Hb (P = 0003, HR 069, 95% CI 054 and 088). Para-
plegia appeared not to be a significant prognostic factor in
this study compared to the previous Malawian study
although the number of patients were too small for meaning-
ful analysis (Depani et al, 2015).
Discussion
The results from this protocol are very encouraging for all
those working in areas where endemic BL is prevalent. The
addition of doxorubicin to the 2010 Malawi protocol
(Depani et al, 2015) for higher stage disease (stage III and
IV) has resulted in an improved DFS from 28% to 663% %
for stage III/IV disease (Fig 2). DFS for all patients has
improved, from 45% to 722%. The improvement in OS was
0·0
0·2
0·4
0·6
0·8
1·0
1 stage 3/4 Current
stage 3/4 Previous
stage 3/4 Current
stage 3/4 Previous
0 4 8 12 16 20 24 28 0 4 8 12 16 20 24
0·0
0·2
0·4
0·6
0·8
1·0
142 35 32 26 23 23 17 8 7 4 2 2 1
47 34 24 19 16 14 12 9 6 2 1 1
42 35 33 29 26 25 18 9 7 4 2 2
47 41 35 30 25 23 19 16 12 8 6 3
P = 0·35P = 8x10–4
Disease-Free survival (months) Overall survival (months)
Pr
op
or
tio
n
Pr
op
or
tio
n
(A) (B)
Fig 2. Disease-free (A) and overall survival (B) for the current and previous (Depani et al, 2015) studies. Kaplan–Meier plot shows proportion
surviving for each disease stage. At-risk tables are shown. P-values, assessed by log-rank test are shown for each plot.
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not statistically significant although a trend was seen. This is
probably due to the fact that seven children died of pre-
sumed sepsis during initial therapy (four prior to doxoru-
bicin) which is five more than the previous study (one died
in week 1 and one in week 2) (Depani et al, 2015). In keep-
ing with the increase in death rate prior to treatment, this is
suggestive that late presentation and poor condition prior to
treatment is more likely to be the reason for these early
deaths. In addition, the majority of early deaths were prior
to the administration of doxorubicin. The increase in early
mortality from presumed sepsis is therefore unlikely to be
solely due to the addition of doxorubicin. The one-year DFS
is a recognised end point for endemic BL and was reinforced
by this study with a median time to relapse of 5 months,
and the latest relapse occurring at 71 months (Hesseling
et al, 2005; Magrath, 2012; Molyneux et al, 2012).
Other potential reasons for this improved outcome have
been investigated. The study population, apart from the male
to female ratio of nearly 1:1 in this study compared to
13–15, is comparable to that seen in other studies in similar
settings (Hesseling et al, 2003, 2005, 2008a, 2009, 2012;
Depani et al, 2015). The comparative numbers given in
Table I suggest that HIV status, presence of malaria at diag-
nosis, rate of malnutrition at diagnosis, median age at pre-
sentation and site of disease were all within the expected
range. Analysis of patients was performed in the same way as
the previous studies (Hesseling et al, 2003, 2005, 2008a,
2009; Depani et al, 2015) to ensure that the improvement in
outcome was not a result of bias in the analysis. Importantly,
there was no statistical difference between the patients in the
two studies. (Table II).
There was an increase in the number of children dying
during treatment, mainly due to presumed sepsis [12% vs.
3–6% in the previous three studies (Hesseling et al, 2008a,
2009; Depani et al, 2015)]. This may have been partly due to
the increased toxicity following the use of anthracyclines,
resulting in an increased incidence of sepsis. Doxorubicin is
used in the treatment of the majority of tumours other than
BL (Isra€els et al, 2013a; Carey et al, 2014) but, in the context
of a rapidly growing tumour, increased vigilance is needed.
The International Society of Paediatric Oncology– Paediatric
Oncology in Developing Countries (SIOP PODC) supportive
guidelines (Israels et al, 2013b) were followed. Pedal oedema
was found to be a significant risk factor in determining sur-
vival and it is postulated that this is a surrogate marker for
malnutrition.
The overall incidence of HIV infection in Malawian chil-
dren is 3% (UNAIDS, 2014) and in the present study only
three children who presented with BL had concurrent infec-
tion. All three of these children died of BL, one within a few
days of treatment starting, one in week 3 of treatment and
one at 4 months post-treatment.
These results are amongst the best in Sub-Saharan Africa
and may show an improvement from studies in countries
such as Cameroon, particularly for stage III/IV disease, of
27% vs. 663% (Hesseling et al, 2008a, 2012; Orem et al,
2011). These results need verification in a separate study
before being widely recommended. Although the outcome of
children in resource-rich countries with sporadic BL is above
90% (Patte et al, 2007; Gerrard et al, 2008), this is achieved
with high intensity treatment and sophisticated supportive
care, which is not possible in the resource-challenged world.
An attempt to use intensive anthracycline-based treatment
[CHOP (cyclophosphamide, doxorubicin, vincristine, pred-
sisone) 9 6] in Lilongwe, Malawi resulted in a toxic death
rate of 40% and OS of 29% and is a useful reminder that
using risk-adapted protocols is necessary in low income set-
tings (Stanley et al, 2016). However the team in Blantyre has
shown that, with dedicated and informed medical and nurs-
ing teams, even the world’s poorest countries can make sig-
nificant improvements to survival in some childhood
tumours.
Caution should be used when using historical controls
due to often-unquantifiable changes, such as supportive care,
experience of staff in treating a particular disease and
changes in demographics. However, in this study there were
no major supportive changes from the last treatment proto-
col that would explain the difference.
Future treatment options to further improve the out-
come are under consideration. These include the use of
high dose methotrexate (1 g/m2) during initial treatment
or the use of agents such as rituximab. The dose of
methotrexate is limited by the inability to measure
methotrexate levels. Without the ability to measure
methotrexate levels in Malawi, higher doses are deemed
unsafe to deliver. Rituximab is both effective and tolerable
in the majority of settings, but its use is limited by its
cost in resource-poor settings. Should rituximab be afford-
able either by cost reduction or by demonstrating efficacy
in smaller doses then this would be likely to become an
important agent in improving survival for children with
BL in low and middle income countries. Any increase in
treatment intensity must be balanced against the ability of
the children and their families to cope with the treatment,
physically as well as being able to spend more time in
hospital away from their familial responsibilities. Any
increase in treatment intensity must also be supported by
improvements in supportive care.
Anthracyclines used in treatment of endemic BL may
improve the outcome of this disease. Further studies in other
countries should be performed to confirm this result.
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